SCHEMBL7440966

SCHEMBL7440966

OCCCCc1cccc(Br)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.46
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TBXAS1 P24557 2/20 0.35
FAAH O00519 1/20 0.34
PARP1 P09874 1/20 0.33
KCNH3 Q9ULD8 1/20 0.33
MBOAT4 Q96T53 1/20 0.32
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7443082 0.94 KCNH2 (0.42) KCNH2KDM1AMAOAMAOBALDH1A1
SCHEMBL1020532 0.86 KCNH2 (0.39) KCNH2KDM1AMAOAMAOBALDH1A1
SCHEMBL2567286 0.86 KCNH2 (0.59) KCNH2ALDH1A1HPGDKDM4EGAA
SCHEMBL7498129 0.82 ALDH1A1 (0.38) KCNH2ALDH1A1HPGDFAAH
SCHEMBL5907729 0.81 KCNH2 (0.71) KCNH2
SCHEMBL14835968 0.80 KCNH2 (0.44) KCNH2KDM1AMAOAMAOBALDH1A1
SCHEMBL25215533 0.79 KCNH2 (0.75) KCNH2
SCHEMBL12747702 0.79 KCNH2 (0.48) KCNH2KDM1AMAOAMAOBFAAH
SCHEMBL12747764 0.79 KCNH2 (0.75) KCNH2
SCHEMBL12747694 0.79 KCNH2 (0.48) KCNH2KDM1AMAOAMAOBFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2480554-B1 MACROCYCLIC INHIBITORS OF JAK HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8318764-B2 Macrocyclic inhibitors of JAK ROCHE PALO ALTO LLC (US) 2012-11-27 US disclosed
US-8318764-B2 Macrocyclic inhibitors of JAK ROCHE PALO ALTO LLC (US) 2012-11-27 US disclosed
WO-2011033053-A1 MACROCYCLIC INHIBITORS OF JAK F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20110071179-A1 MACROCYCLIC INHIBITORS OF JAK JAHANGIR ALAM 2011-03-24 US disclosed
US-20110071179-A1 MACROCYCLIC INHIBITORS OF JAK JAHANGIR ALAM 2011-03-24 US disclosed
US-6028087-A Platelet aggregation inhibiting compounds SMITHKLINE BEECHAM CORPORATION (US) 2000-02-22 US disclosed
EP-0677043-A4 1995-11-22 EP disclosed
EP-0677043-A1 PLATELET AGGREGATION INHIBITING COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1995-10-18 EP disclosed
WO-1994014775-A1 PLATELET AGGREGATION INHIBITING COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071179-A1 MACROCYCLIC INHIBITORS OF JAK JAK2, JAK1, JAK3 KCNH2 2447/4885KDM1A 776/4885MAOA 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.